2. Signaling Pathways
  3. Immunology/Inflammation
  4. CD47

CD47

Cluster of Differentiation 47; MER6; OA3

CD47 is a glycoprotein that was first identified in 1990 as a protein that associates with integrins, hence its original name integrin-associated protein. CD47 interacts with SIRPα (CD172a or SHPS-1) and its family member SIRPγ, CD47 also interacts with integrins and secreted glycoprotein extracellular matrix protein thrombospondin-1 (TSP-1). Signaling through the CD47/SIRPα axis plays a role in various homeostatic processes, such as maintenance of erythrocytes, innate immune cells and T cells. Moreover, cancer cells and virus-infected and bacteria-infected cells can upregulate CD47 protein expression to prevent immune-mediated elimination.

CD47 Related Products (38):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P990555
    BI-765063
    		Inhibitor
    BI-765063 is a humanized antibody expressed in CHO that targets SIRPa/CD172a. BI-765063 contains an IgG4PE type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 144.36 kDa. The isotype control for BI-765063 can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
    BI-765063
  • HY-143224
    NCGC00138783
    		Inhibitor
    NCGC00138783 is a selective inhibitor targeting CD47/SIRPα axis, with an IC50 of 50 µM. NCGC00138783 directly blocks the interaction between CD47 and SIRPα axis.
    NCGC00138783
  • HY-P990131
    Anti-Mouse CD47/IAP Antibody (MIAP301)
    		Inhibitor
    Anti-Mouse CD47/IAP Antibody (MIAP301) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse CD47/IAP.
    Anti-Mouse CD47/IAP Antibody (MIAP301)
  • HY-P990694
    Zeripatamig
    		Inhibitor
    Zeripatamig is an anti-CD19/CD47 human IgG1 κ monoclonal antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
    Zeripatamig
  • HY-P99950
    Evorpacept
    		Inhibitor
    Evorpacept is a high affinity CD47-blocking fusion protein with an inactive human immunoglobulin Fc region.
    Evorpacept
  • HY-P990954
    Amulirafusp alfa
    HY-P990954 is an MS4A1/CD47-targeting IgG1κ type human antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001).
    Amulirafusp alfa
  • HY-P991023
    Safimestomig
    HY-P991023 is an CD47/CD274-targeting IgG4κ type bispecific antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
    Safimestomig
  • HY-P990707
    Maplirpacept
    Maplirpacept (TTI-622; PF-07901801) is a fusion protein consisting of the CD47-binding domain of human SIRPα linked to the Fc region of human IgG4. Maplirpacept enhances phagocytosis by blocking CD47.
    Maplirpacept
  • HY-P991016
    Peluntamig
    HY-P991016 is an CD47/DLL3-targeting H-γ1_L-κ type bispecific antibody.
    Peluntamig
  • HY-P3968
    Thrombospondin-1 (1016-1021) (human, bovine, mouse)
    Thrombospondin-1 (1016-1021) (human, bovine, mouse), a Thrombospondin-1-derived peptide, is a truncated peptide devoid of CD47-binding activity.
    Thrombospondin-1 (1016-1021) (human, bovine, mouse)
  • HY-P990723
    Timdarpacept
    		Inhibitor
    Timdarpacept (DNL310) is a recombinant SIRPa-Fc fusion protein that can activate macrophages to enhance anti-tumor activity by blocking CD47-SIRPa.
    Timdarpacept
  • HY-P991062
    Gentulizumab
    		Inhibitor
    Gentulizumab (Gensci-059) is a humanized IgG4 antibody that targets CD47. Gentulizumab displays strong binding to CD47 in both human and monkey, and effectively inhibits the CD47-SIRPα interaction. Gentulizumab exhibits a potent antitumor activity. The isotype control for Gentulizumab can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
    Gentulizumab
  • HY-P10813
    ZLIRTLHEWY
    		Inhibitor
    ZLIRTLHEWY is a potent peptide CD47/SIRPα interaction inhibitor. ZLIRTLHEWY is promising for research of cancers.
    ZLIRTLHEWY
  • HY-143224A
    NCGC00138783 free base
    		Inhibitor
    NCGC00138783 free base is a selective inhibitor targeting CD47/SIRPα axis, with an IC50 of 50 µM. NCGC00138783 free base directly blocks the interaction between CD47 and SIRPα axis.
    NCGC00138783 free base
  • HY-P10420
    RS17
    		Inhibitor 99.82%
    RS17 is an anti-tumor peptide designed to bind specifically to the CD47 molecule and block the interaction between CD47 and its ligand, SIRPα, on the surface membrane of macrophages. The main regulatory mechanism of RS17 is to prevent CD47 from transmitting selective phagocytosis signals to SIRPα by binding to CD47, so that macrophages do not recognize tumor cells as their own tissue, but phagocytose them as foreign substances, thereby inhibiting immune escape of tumor cells. RS17 can be used to study the mechanism of anti-tumor response and immune escape.
    RS17
  • HY-143225
    NCGC00538431
    		Inhibitor
    NCGC00538431 is a potent modulator of SIRPα-CD47.
    NCGC00538431
  • HY-RS02250
    CD47 Human Pre-designed siRNA Set A
    		Inhibitor

    CD47 Human Pre-designed siRNA Set A contains three designed siRNAs for CD47 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    CD47 Human Pre-designed siRNA Set A
    CD47 Human Pre-designed siRNA Set A
  • HY-P991057
    STI-6643
    		Inhibitor
    STI-6643 is a fully human IgG4 antibody that targets CD47. STI-6643 displays potent anti-tumor activity with negligible RBC and lymphocyte toxicities. The isotype control for STI-6643 can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
    STI-6643